FibroBiologics FY2025 EPS Forecast Boosted by HC Wainwright

FibroBiologics, Inc. (NASDAQ:FBLG) – Investment analysts at HC Wainwright upped their FY2025 earnings estimates for FibroBiologics in a report released on Tuesday, April 1st. HC Wainwright analyst M. Caufield now forecasts that the company will post earnings of ($0.44) per share for the year, up from their prior forecast of ($0.46). HC Wainwright currently has a “Buy” rating and a $12.00 target price on the stock. The consensus estimate for FibroBiologics’ current full-year earnings is ($0.53) per share. HC Wainwright also issued estimates for FibroBiologics’ FY2026 earnings at ($0.56) EPS, FY2027 earnings at ($0.76) EPS and FY2028 earnings at ($0.76) EPS.

FibroBiologics (NASDAQ:FBLG) last issued its quarterly earnings results on Monday, March 31st. The company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.10) by $0.01.

A number of other research firms also recently commented on FBLG. D. Boral Capital reaffirmed a “buy” rating and set a $16.00 price objective on shares of FibroBiologics in a research note on Tuesday. Rodman & Renshaw started coverage on shares of FibroBiologics in a research report on Thursday, December 12th. They set a “buy” rating and a $12.00 price target for the company. Four analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $13.00.

FibroBiologics Trading Up 0.1 %

FibroBiologics stock opened at $0.88 on Thursday. The stock has a fifty day moving average price of $1.23 and a 200 day moving average price of $2.11. FibroBiologics has a 52 week low of $0.85 and a 52 week high of $13.59.

Institutional Trading of FibroBiologics

Institutional investors have recently modified their holdings of the company. Intech Investment Management LLC purchased a new position in FibroBiologics in the fourth quarter valued at approximately $25,000. Virtu Financial LLC acquired a new stake in shares of FibroBiologics in the fourth quarter worth $30,000. The Manufacturers Life Insurance Company purchased a new position in shares of FibroBiologics in the 3rd quarter valued at $32,000. Jane Street Group LLC acquired a new position in shares of FibroBiologics during the 3rd quarter valued at $37,000. Finally, Raymond James Financial Inc. purchased a new stake in FibroBiologics during the 4th quarter worth $37,000.

About FibroBiologics

FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer.